Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19598750 | 0.84 | HPGD (0.38) | THRBMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL19580900 | 0.83 | THRB (0.36) | THRBMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL25603625 | 0.82 | PPARA (0.41) | THRBMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL19600791 | 0.82 | GAA (0.36) | THRBTP53HPGD | |
| SCHEMBL21404987 | 0.81 | CYP4F2 (0.36) | THRBMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL24102993 | 0.80 | THRB (0.37) | THRBMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL25603634 | 0.80 | THRB (0.34) | THRBMEN1KMT2AALDH1A1TP53 | |
| SCHEMBL19580987 | 0.78 | LMNA (0.40) | ALDH1A1NPC1RAB9A | |
| SCHEMBL19580803 | 0.78 | PSMD10 (0.37) | KMT2AALDH1A1TP53NPC1RAB9A | |
| SCHEMBL25602286 | 0.76 | POLB (0.43) | THRBMEN1KMT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055825-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055825-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | THRB 639/4885MEN1 2815/4885KMT2A 1478/4885 |
| US-20170327469-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, MDM2, ESRRA | THRB 639/4885MEN1 2815/4885KMT2A 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.